Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study

Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., ...More

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 30
  • City: Illinois
  • Country: United States Of America
  • Hacettepe University Affiliated: Yes